All the resolutions proposed by the Board of Directors were approved at the Annual General Meeting that took place today in Geneva. This included the approval of the scrip dividend proposal.
Schultz who stepped down at the end of 2022 after five years at the helm will receive a further $16 million in 2023 from the Israeli pharmaceutical company.